A5015561101- Prostate Cancer Treatment and Research
- Advanced Radiotherapy Techniques
- Prostate Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Lung Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Brain Metastases and Treatment
- Renal cell carcinoma treatment
- Glioma Diagnosis and Treatment
- Management of metastatic bone disease
- Advanced X-ray and CT Imaging
- Sarcoma Diagnosis and Treatment
- Healthcare Systems and Public Health
- Energy and Environmental Sustainability
- Economic and Technological Developments in Russia
- Nanoplatforms for cancer theranostics
- Cancer, Hypoxia, and Metabolism
- Cancer Diagnosis and Treatment
- Breast Implant and Reconstruction
- Endometrial and Cervical Cancer Treatments
- Histone Deacetylase Inhibitors Research
- Inhalation and Respiratory Drug Delivery
- Health Systems, Economic Evaluations, Quality of Life
- Radiation Dose and Imaging
IRCCS Humanitas Research Hospital
2022-2024
Humanitas University
2020-2023
Azienda Ospedaliero-Universitaria Careggi
2023
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2022
Azienda Ospedaliera Universitaria Pisana
2018-2020
University of Pisa
2017-2019
Radiation Oncology Associates
2018
The Christie NHS Foundation Trust
2018
Humanitas Gavazzeni
2018
PSICHE (NCT05022914) is a prospective trial to test [68Ga]Ga- PSMA-11 PET/CT imaging tailored strategy. All evaluable patients had biochemical relapse after surgery and underwent centralized [68Ga]Ga-PSMA-11 imaging. The treatment was performed according pre-defined criteria. Observation re-staging at further PSA progression were proposed with negative PSMA previous postoperative RT. Prostate bed SRT all staging or positive within prostate bed. Stereotactic body radiotherapy (SBRT) sites of...
Abstract Background In the last years, functional imaging has given a significant contribution to clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present prospective study aiming validate role [ 18 F]Fluoro-Methyl Choline ([ F]FMCH) PET/CT in selection PCa patients suitable for stereotactic body radiotherapy (SBRT). Methods Patients with biochemical recurrence limited up three lesions revealed by F]FMCH were enrolled and treated SBRT on all active...
BackgroundWhile SBRT to the prostate has become a valuable option as radical treatment, limited data support its use in postoperative setting. Here, we report updated results of multicentric Post-Prostatectomy Ablative Radiation Therapy (POPART) trial, investigating possible predictors toxicities and patient-reported outcomes.MethodsPatients with PSA levels ≥0.1–2.0 ng/mL after prostatectomy received Linac-based bed five fractions every other day for total dose 32.5 Gy (EQD21.5 =74.3 Gy)....
Background/Aim: In the last years, use of Image Guided Stereotactic Radiotherapy (IG-SBRT) in patients with metastatic prostate cancer has increased. this study, we aimed to assess role IG-SBRT terms local control and safety cancer. Materials Methods: Primary secondary endpoints prospective observational study were related IG-SBRT. All lesions treated 24 Gy as a single fraction or 27 3 fractions. After SBRT, Systemic therapies administered only after occurrence more than three synchronous...
Background: The aim of this study was to investigate the feasibility ultrahypofractionated radiotherapy prostate bed in patients with biochemical and/or clinical relapse following radical prostatectomy who were enrolled prospective, observational, multicentric POPART trial (NCT04831970). Methods: Patients post-radical PSA levels ≥0.1–2.0 ng/mL local at PSMA PET/CT or multiparametric MRI treated Linac-based SBRT on up a total dose 32.5 Gy five fractions every other day (EQD21.5 = 74.2 Gy)....
The aim of this article was to offer a comprehensive non-systematic review the literature about use Nuclear Medicine imaging exams for evaluation prostate cancer (PCa) in recurrent setting, with particular regard positron emission tomography/computed tomography (PET/CT) imaging.
Background/Aim: In patients with recurrent glioblastoma, the best timing to administer bevacizumab is not well addressed yet. this study, we reported results of a monocentric experience comparing early use (following first GBM recurrence) delayed administration second or even further recurrences). Materials and Methods: This analysis included 129 glioblastoma median follow-up 22.4 months (range=5.26-192 months). Results: The time lapse from diagnosis disease recurrence was 11.6 months; 13.1...
<b><i>Background:</i></b> The aim of this study was to assess the treatment benefit and patterns recurrence for patients with high-risk vulvar squamous cell carcinoma treated surgery followed by adjuvant radiotherapy (RT). <b><i>Patients Methods:</i></b> From January 1999 June 2016, 51 underwent total or partial deep vulvectomy inguinofemoral lymphadenectomy RT 45-50 Gy in 25 fractions +/- a 4-10 boost. 17 (33.3%) women received concomitant...
Bevacizumab is an anti-vascular endothelial growth factor antibody used in the treatment of recurrent glioblastoma (GBM). Despite large number studies carried out patients with GBM, little known about administration this angiogenesis inhibitor after failure second-line chemotherapy.In retrospective multicenter study, on behalf Italian Association Neuro-Oncology, we reported results obtained 51 GBM treated single-agent bevacizumab chemotherapy fotemustine.In March 2016, at time data analysis,...
Ultrasensitive imaging has been demonstrated to influence biochemical relapse treatment. PSICHE is a multicentric prospective study, aimed at exploring detection rate with 68Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT) and outcomes predefined treatment algorithm tailored the imaging.Patients affected by recurrence after surgery (prostate specific antigen [PSA] > 0.2 < 1 ng/mL) underwent staging 68Ga-PSMA PET/CT. Management followed this accordingly PSMA results:...
Abstract Background In 2016 we published a phase II study exploring safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) delivered with Volumetric Modulated Arc (VMAT) Flattening Filter Free (FFF) beams techniques in prostate cancer (PC) patients. We present herein the updated results on late toxicity long‐term survival. Methods Patients enrolled had biopsy‐confirmed localized PC features low‐ or intermediate‐risk disease (National Comprehensive Network Criteria). The...
Gangliogliomas are rare tumor usually arising in the supratentorial region, WHO grade 1 or 2. In these tumors, BRAF mutation may constitute a driver genetic alteration and biomarker of response to inhibitors. Dabrafenib is an oral inhibitor has shown significantly improve progression-free survival patients with mutated metastatic melanoma. March 2015, after being diagnosed left front-temporal enhancing mass, 31-year-old lady was referred University Hospital Pisa. previous two months, patient...
Abstract Background Distant Metastases from Head and Neck Squamous cell carcinomas are uncommon (9–11%) they usually found in the lung less frequently liver, kidney adrenals. Central nervous system (CNS) metastases extremely rare (2–8%), described mainly patients who already have extracranial metastases. So there’s scarcity of data about their optimal management . Methods results A patient presented CNS after having been successfully treated with induction chemotherapy definitive...
This study evaluated the outcome, toxicity and predictive factors in patients unfit for concurrent chemo-radiotherapy (CT-RT) treated with hypofractionated sequential CT-RT or exclusive radiotherapy (RT) locally advanced non-small cell lung cancer (LA-NSCLC).We included affected by LA-NSCLC (stage IIA-IVA) a total dose of 50-60 Gy 20 fractions. The primary outcomes were local control (LC), distant metastasis-free survival (DMFS), progression-free (PFS) overall (OS). Univariate analysis was...